{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:53:31Z","timestamp":1773294811726,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.dld.2016.11.002","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T03:15:33Z","timestamp":1479093333000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Adalimumab dose escalation is effective and well tolerated in Crohn\u2019s disease patients with secondary loss of response to adalimumab"],"prefix":"10.1016","volume":"49","author":[{"given":"Nicolas","family":"Duveau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Branche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Maunoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medina","family":"Boualit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Desreumaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.11.002_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2014.09.015","article-title":"Development of the L\u00e9mann index to assess digestive tract damage in patients with Crohn\u2019s disease","volume":"148","author":"Pariente","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.21010","article-title":"Disability in inflammatory bowel diseases: developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health","volume":"16","author":"Peyrin-Biroulet","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.11.002_bib0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis","volume":"123","author":"Pearson","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2016.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease","volume":"342","author":"Feagan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.11.002_bib0025","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2016.11.002_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0035","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"10.1016\/j.dld.2016.11.002_bib0045","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0050","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"10.1016\/j.dld.2016.11.002_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.crohns.2010.05.011","article-title":"Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists","volume":"4","author":"Chowers","year":"2010","journal-title":"Journal of Crohns and Colitis"},{"key":"10.1016\/j.dld.2016.11.002_bib0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2016.11.002_bib0065","first-page":"9170","article-title":"Need for infliximab dose intensification in Crohn\u2019s disease and ulcerative colitis","volume":"20","author":"Taxonera","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.crohns.2011.07.005","article-title":"Intensification of infliximab therapy in Crohn\u00eds disease: efficacy and safety","volume":"6","author":"Chaparro","year":"2012","journal-title":"Journal of Crohns and Colitis"},{"key":"10.1016\/j.dld.2016.11.002_bib0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2036.2010.04523.x","article-title":"The efficacy of shortening the dosing interval to once every six weeks in Crohn\u2019s patients losing response to maintenance dose of infliximab","volume":"33","author":"Kopylov","year":"2011","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"Suppl. A","key":"10.1016\/j.dld.2016.11.002_bib0080","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","article-title":"Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\u2019s patients","volume":"7","author":"Baert","year":"2013","journal-title":"Journal of Crohns and Colitis"},{"key":"10.1016\/j.dld.2016.11.002_bib0090","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.12940","article-title":"Adalimumab dose escalation is effective for managing secondary loss of response in Crohn\u2019s disease","volume":"40","author":"Ma","year":"2014","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"10.1016\/j.dld.2016.11.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)30216-X","article-title":"Efficacy of adalimumab in patients with Crohns disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE)","volume":"148","author":"Bouhnik","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.11.002_bib0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2016.11.002_bib0105","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ibd.21839","article-title":"Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease","volume":"18","author":"Pariente","year":"2012","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086581630785X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086581630785X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:20:26Z","timestamp":1536247226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086581630785X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S159086581630785X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.11.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab dose escalation is effective and well tolerated in Crohn\u2019s disease patients with secondary loss of response to adalimumab","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}